Related Experiment Videos
Risk assessment and anticoagulation for primary stroke prevention in atrial fibrillation
1Orpington Stroke Unit, Clinical and Health Services Studies Unit, King's College School of Medicine & Dentistry, London, UK. lalit.kalra@jck.ac.uk
Insights
Clinical risk assessment alone is sufficient for anticoagulation decisions in atrial fibrillation (AF), particularly for older patients. Echocardiography (ECHO) offers limited additional value, mainly for younger patients without clinical risk factors.
Area of Science:
- Cardiology
- Internal Medicine
- Geriatrics
Background:
- Stroke prevention in atrial fibrillation (AF) necessitates accurate pre-anticoagulation risk assessment.
- Clinical and echocardiography (ECHO) criteria play roles in guiding anticoagulation therapy decisions.
Purpose of the Study:
- To investigate the contribution of clinical and ECHO criteria to anticoagulation treatment decisions in AF patients.
- To evaluate the impact of age on risk assessment and anticoagulation practices.
- To assess the utility of ECHO in refining treatment decisions.
Main Methods:
- A study involving 234 AF patients stratified by age and stroke risk.
- Assessment of contraindications to anticoagulation and current warfarin use.
- Evaluation of ECHO's role, age effects, and existing anticoagulation practices.
Main Results:
- Older patients (>75 years) had higher rates of clinical risk factors (92%) compared to younger patients (64%).
- ECHO identified risk in 61% of patients ≤75 years and 88% of patients >75 years.
- Anticoagulation eligibility varied by criteria in younger patients but was high in older patients; warfarin use was significantly lower in older patients.
Conclusions:
- Clinical criteria alone are adequate for assessing anticoagulation eligibility and appropriateness in AF, especially in the elderly.
- Echocardiography provides incremental value primarily for patients ≤75 years without identifiable clinical risk factors.
Background And Purpose:
Risk assessment before anticoagulation is important for effective stroke prevention in atrial fibrillation (AF).
Methods:
A study was undertaken in patients with AF to investigate the contribution of clinical and echocardiography (ECHO) criteria to treatment decisions on anticoagulation. Patients were stratified by age and stroke risk; contraindications to anticoagulation and warfarin use were assessed. The value of ECHO in treatment decisions, effect of age, and existing anticoagulation practice were evaluated.
Results:
The mean+/-SD age of 234 patients was 67.1+/-11.8 years, and 122 (52%) were women. Clinical risk factors were present in 74 of 80 patients (92%) aged >75 years compared with 99 of 154 patients (64%) 75 years of age, and was associated with clinical risk factors in all patients. Eligibility for anticoagulation was seen in 72 of 154 (47%) to 105 of 154 (68%) patients aged 75 years, regardless of criteria used (P<0.01). Warfarin was being used in 55 of 105 patients (51%) 75 years (P<0.001). Anticoagulation was being undertaken in 7 of 49 patients (14%)
Conclusions:
Accurate assessments of eligibility and appropriateness of anticoagulation in AF can be made on clinical criteria alone, especially in older people. The value of ECHO in treatment decisions is limited to patients